Digital Pathology Market Size Projected to Reach $3.49 billion by 2034 | 8.68%

According to Straits Research, the global Digital Pathology Market size was valued at $1.47 billion in 2025 and is projected to grow from $1.59 billion in 2026 to $3.09 billion by 2034, registering a CAGR of 8.43% during the forecast period (2026–2034).

Digital pathology integrates the collection, management, sharing, and analysis of pathology knowledge, including slides and data, in a digital world. Glass slides are created to have a high-resolution digital image that can be displayed on a computer screen or mobile device when glass slides are collected with a scanning tool. The rapid development of whole slide imaging (WSI) technology, coupled with innovations in software applications, LIS / LIMS interfacing, and high-speed networking, has enabled the complete integration of digital pathology into pathology workflows.

Digital pathology helps pathologists to easily and remotely communicate, analyze, and collaborate, with clarity and accuracy, thus increasing performance and productivity. Eventually, the future of digital pathology will include improved translational testing, computer-aided diagnosis (CAD), and personalized medicine.Over the years, digital pathology has created a new forum for clinical pathology, enabling convenient and accurate data sharing for diagnostic and multi-research pathology studies between scientists and laboratory technicians. Digital pathology is a promising sector within In-Vitro Diagnostics (IVD). Its case use extends to hospitals, research labs, pathologists, teaching and research institutes and pharmaceutical companies.

Impact of COVID-19

Digital pathology is more important than ever amid the coronavirus pandemic. The most successful way to reduce the possibility of transmission is by encouraging pathologists to practice social distancing by encouraging remote research. Pathologists can work from home and monitor their microscopes remotely, display slides in real-time and from uploaded collections, exchange information with colleagues, and continue to provide remote diagnostics.

In April 2020, the FDA issued an immediate in effect guidance, ‘Enforcement Policy for Remote Digital Pathology Devices’ during ‘COVID-19 Public Health Emergency’, to extend the availability of devices for remote reviewing and reporting of scanned digital images of pathology slides.

Key Highlights

• The global Digital Pathology Market size was valued at $1.47 billion in 2025.
• The software segment is projected to see lucrative growth in the near future as the product helps to diagnose and synchronize patient data faster, where healthcare professionals to access this information remotely.
• The availability of coherent workflow systems in pathology is expected to increase the use of computer-aided imaging technology in clinical research.
• In August 2019, Leica Biosystems (US) launched the Aperio GT 450
• In January 2019, Roche launched uPath enterprise software with improved speed, performance, and usability for digital pathology.
• In June 2018, Royal Philips, a Dutch company, acquired the Irish PathXL, one of the largest image-based pathology analytics firms. This acquisition was conducted to develop advanced tools targeting computational biology, workflow solutions, education, and image analytics applications.
• Some of the key players profiled in the global digital pathology market are Leica Biosystems, Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd, 3DHISTECH, Apollo Enterprise Imaging, XIFIN, Huron Digital Pathology, Visiopharm A/S., Corista, Indica Labs, Objective Pathology Services, Sectra AB, OptraSCAN, Glencoe Software, Inspirata, Inc., Mikroscan Technologies, Proscia Inc. and Kanteron Systems.

Market Segments

1. By Product
   1. Scanners
   2. Software
   3. Communication Systems
   4. Storage Systems
2. By Type
   1. Human Pathology
   2. Veterinary Pathology
3. By Application
   1. Drug Discovery
   2. Disease Diagnosis
   3. Teleconsultation
   4. Training and Education
4. By End-User
   1. Pharmaceutical and Biotechnology Companies
   2. Hospitals and Reference Laboratories
   3. Academic & Research Institutes
5. By Regions
   1. North America
   2. Europe
   3. Asia Pacific
   4. Central, South America, and the Caribbean
   5. Middle East and Africa